Development and Psychometric Evaluation of an Instrument Assessing Barriers to Growth Hormone Treatment (BAR-GHT)

Martina de Zwaan, Josefine Fischer-Jacobs, Martin Wabitsch, Thomas Reinehr, Stefanie Meckes-Ferber, Ross D Crosby, Martina de Zwaan, Josefine Fischer-Jacobs, Martin Wabitsch, Thomas Reinehr, Stefanie Meckes-Ferber, Ross D Crosby

Abstract

Purpose: This paper presents development and validation of a new patient reported outcome measure (PRO), the Barriers to Growth Hormone Therapy (BAR-GHT) in a patient (child/adolescent) and a parent version. The BAR-GHT was developed to measure problems and potential barriers to GHT. Methods: The development and validation of the BAR-GHT was conducted according to the Food and Drug Administration (FDA) Guidance on the development of PROs. Concept elicitation included a literature review and open-ended interviews with young patients, parents, and clinical experts. Qualitative data were analyzed based on grounded theory principles and draft items were rated in terms of their importance and clarity. The instruments underwent psychometric validation in a German clinic-based patient population of children and adolescents who inject themselves and in a parent sample who inject their child. The statistical analysis plan included exploratory factor analysis, reliability, and validity. Results: 29 patients, 22 parents, and 4 clinical experts participated in the concept elicitation, 156 children and adolescents aged 8-18 years and 146 parents completed the validation study. Exploratory factor analysis resulted in six domains: Fear, Public Embarrassment, Annoyance, Daily Routine, Supplies, and Travel. Internal consistencies and test-retest reliabilities of the total score of both the patient version and the parent version were >0.8. Convergent and discriminant validity was demonstrated. Conclusions: The final 19-item BAR-GHT for patients aged 8-18 years and the 16-item version for parents can be considered reliable and valid PROs of barriers to GHT. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT03672617. Universal Trial Number (UTN) of the International Clinical Trials Registry Platform (ICTRP, www.who.int): U1111-1210-1036.

Keywords: adherence; barriers; factor analysis; growth hormone therapy; patient reported outcome measure.

Copyright © 2020 de Zwaan, Fischer-Jacobs, Wabitsch, Reinehr, Meckes-Ferber and Crosby.

References

    1. Hoepffner W, Pfaffle R, Gausche R, Meigen C, Keller E. Early detection of growth disorders with the CrescNet system at the Leipzig treatment center. Dtsch Arztebl Int. (2011) 108:123–8. 10.3238/arztebl.2011.0123
    1. Geisler A, Lass N, Reinsch N, Uysal Y, Singer V, Ravens-Sieberer U, et al. . Quality of life in children and adolescents with growth hormone deficiency: association with growth hormone treatment. Horm Res Paediatr. (2012) 78:94–9. 10.1159/000341151
    1. Sandberg DE, Gardner M. Short stature: is it a psychosocial problem and does changing height matter? Pediatr Clin North Am. (2015) 62:963–82. 10.1016/j.pcl.2015.04.009
    1. Ranke MB, Wit JM. Reflections on the US guidelines on growth hormone and insulin-like growth factor-I treatment in children and adolescents. Horm Res Paediatr. (2016) 86:398–402. 10.1159/000452446
    1. Cutfield WS, Derraik JG, Gunn AJ, Reid K, Delany T, Robinson E, et al. . Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS ONE. (2011) 6:e16223. 10.1371/journal.pone.0016223
    1. Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Paediatr. (2013) 79:189–96. 10.1159/000350251
    1. Graham S, Weinman J, Auyeung V. Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review. Horm Res Paediatr. (2018) 90:221–7. 10.1159/000493211
    1. Lass N, Reinehr T. Low treatment adherence in pubertal children treated with thyroxin or growth hormone. Horm Res Paediatr. (2015) 84:240–7. 10.1159/000437305
    1. Rosenfeld RG, Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract. (2008) 14:143–54. 10.4158/EP.14.2.143
    1. Bagnasco F, Di Iorgi N, Roveda A, Gallizia A, Haupt R, Maghnie M, et al. . Prevalence and correlates of adherence in children and adolescents treated with growth hormone: a multicenter Italian study. Endocr Pract. (2017) 23:929–41. 10.4158/EP171786.OR
    1. Katusiime B, Corlett S, Reeve J, Krska J. Measuring medicine-related experiences from the patient perspective: a systematic review. Patient Relat Outcome Meas. (2016) 7:157–71 10.2147/PROM.S102198
    1. US Food and Drug Administration Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Rockville, MD: (2009).
    1. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. (1999) 47:555–67. 10.1016/S0022-3999(99)00057-4
    1. Mahler C, Hermann K, Horne R, Ludt S, Haefeli WE, Szecsenyi J, et al. . Assessing reported adherence to pharmacological treatment recommendations. translation and evaluation of the medication adherence report scale (MARS) in Germany. J Eval Clin Pract. (2010) 16:574–9. 10.1111/j.1365-2753.2009.01169.x
    1. Garcia-Marcos PW, Brand PL, Kaptein AA, Klok T. Is the MARS questionnaire a reliable measure of medication adherence in childhood asthma? J Asthma. (2016) 53:1085–9. 10.1080/02770903.2016.1180699
    1. Wehmeier PM, Dittmann RW, Banaschewski T. Treatment compliance or medication adherence in children and adolescents on ADHD medication inclinical practice: results from the COMPLY observational study. Atten Defic Hyperact Disord. (2015) 7:165–74. 10.1007/s12402-014-0156-8
    1. Alsous M, Abu Farha R, Alefishat E, Al Omar S, Momani D, Gharabli A, et al. . Adherence to 6-mercaptopurine in children and adolescents with acute lymphoblastic leukemia. PLoS ONE. (2017) 12:e0183119. 10.1371/journal.pone.0183119
    1. Ravens-Sieberer U, Gosch A, Abel T, Auquier P, Bellach BM, Dür W, et al. . Quality of life in children and adolescents: a European public health perspective. Soz Praventivmed. (2001) 46:294–302. 10.1007/BF01321080
    1. Goodman R. The strengths and difficulties questionnaire: a research note. J Child Psychol Psychiatry. (1997) 38:581–6. 10.1111/j.1469-7610.1997.tb01545.x
    1. Ware JE, Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the medical outcome study. Med Care. (1995) 33(Suppl. 4):AS264–79.
    1. Mohseni S, Heydari Z, Qorbani M, Radfar M. Adherence to growth hormone therapy in children and its potential barriers. J Pediatr Endocrinol Metab. (2018) 31:13–20. 10.1515/jpem-2017-0157
    1. Quitmann J, Bloemeke J, Silva N, Bullinger M, Witt S, Akkurt I, et al. . Quality of life of short-statured children born small for gestational age or idiopathic growth hormone deficiency within 1 year of growth hormone treatment. Front Pediatr. (2019) 7:164. 10.3389/fped.2019.00164
    1. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. (2011) 6:42. 10.1186/1748-5908-6-42
    1. Jackson C, Eliasson L, Barber N, Weinman J. Applying COM-B to medication adherence. Eur Health Psychol. (2014) 16:7–17.
    1. Bloemeke J, Silva N, Bullinger M, Witt S, Dörr HG, Quitmann J. Psychometric properties of the quality of life in short statured youth (QoLISSY) questionnaire within the course of growth hormone treatment. Health Qual Life Outcomes. (2019) 17:49. 10.1186/s12955-019-1118-9
    1. le Coq EM, Boeke AJ, Bezemer PD, Colland VT, van Eijk JT. Which source should we use to measure quality of life in children with asthma: the children themselves or their parents? Qual Life Res. (2000) 9:625–36. 10.1023/A:1008977200176

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner